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ExportThe human prostacyclin receptor (hIP) undergoes agonist-dependent trafﬁcking involving a direct interaction
with Rab11aGTPase. The region of interactionwas localised to a 14 residue Rab11a binding domain (RBD)within
the proximal carboxyl-terminal (C)-tail domain of the hIP, consisting of Val299–Val307 within the eighth helical
domain (α-H8) adjacent to the palmitoylated residues at Cys308–Cys311. However, the factors determining the
anterograde transport of the newly synthesised hIP from the endoplasmic reticulum (ER) to the plasma
membrane (PM) have not been identiﬁed. The aim of the current studywas to identify themajor ER exportmotif
(s) within the hIP initially by investigating the role of Lys residues in itsmaturation and processing. Through site-
directed andAla-scanningmutational studies in combinationwith analyses of protein expression andmaturation,
functional analyses of ligand binding, agonist-induced intracellular signalling and confocal image analyses, itwas
determined that Lys297, Arg302 and Lys304 located within α-H8 represent the critical determinants of a novel ER
export motif of the hIP. Furthermore, while substitution of those critical residues signiﬁcantly impaired
maturation and processing of the hIP, replacement of the positively charged Lyswith Arg residues, and vice versa,
was functionally permissible. Hence, this study has identiﬁed a novel 8 residue ER export motif within the
functionally important α-H8 of the hIP. This ER export motif, deﬁned by “K/R(X)4K/R(X)K/R,” has a strict
requirement for positively charged, basic Lys/Arg residues at the 1st, 6th and 8th positions and appears to be
evolutionarily conserved within IP sequences from mouse to man.; [Ca2+]i, intracellular calcium;
in-II vesicles; ER, endoplasmic
tracellular; GPCR, G protein-
ryonic kidney; hIP, human IP;
PM, plasma membrane; RBD,
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G protein-coupled receptors (GPCRs), the largest superfamily of
cell surface receptors, play an integral role in signal transduction [1,2].
They recognise and bind an array of extracellular stimuli transducing
signals to a variety of intracellular effector systems to modulate a host
of biological responses [3]. All GPCRs share a common topographical
structure characterised by an amino (N)-terminal extracellular
domain, seven transmembrane (TM)-spanning α helices linked by
three alternating intracellular (IC)1-3 and three extracellular (EC)1–3
loops and a divergent intracellular carboxyl terminal (C)-tail domain.
Additionally, through recent X-ray crystallographic data along with
other experimental and computational approaches, the presence of an
eighth alpha helical domain (α-H8) within the proximal C-tail
domain, adjacent to TM7, has now been recognised as a commonstructural feature in many GPCRs [4,5]. Moreover, the α-H8 is both
functionally important and diverse, having being implicated in the
regulation of receptor-expression and intracellular trafﬁcking, -G-
protein coupling and activation, -agonist-induced internalisation and/
or -dimerisation [6–10].
The prostanoid prostacyclin, or prostaglandin I2, mainly produced
by the vascular endothelium [11], is a potent proinﬂammatory
mediator [12,13] and plays a central role in haemostasis, inhibiting
platelet aggregation and inducing vasodilation [14,15]. Prostacyclin
exerts an important cytoprotective role within the myocardium [16]
and also limits restenosis, promoting vascular repair in response to
injury [17]. Stable prostacyclin analogues are used clinically in the
treatment of pulmonary arterial hypertension [18]. Prostacyclin
mainly signals through interaction with the prostacyclin receptor, or
IP, a member of the GPCR superfamily. The IP is abundantly expressed
throughout the vasculature, in the heart, kidney, lung, thymus and
spleen and in the sensory neurons of the dorsal root ganglion [15,19].
Alterations in the levels of prostacyclin or of the IP have been
implicated in a number of cardiovascular disorders including
myocardial infarction, thrombosis, atherosclerosis and restenosis
[14,20,21]. Additionally, several single nucleotide polymorphisms
have been identiﬁed within the IP gene that may predispose
individuals to cardiovascular disease, including enhanced risk of
deep vein thrombosis and intimal hyperplasia [22,23].
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may also regulate other effectors including Gq-mediated phospholi-
pase (PL)Cβ activation, leading to phosphatidyl inositol turnover and
mobilisation of calcium from intracellular stores [24–29]. The human
(h)IP is subject to a number of co- and post-translational modiﬁca-
tions that are critical to its function. Somewhat typical of other cell-
surface GPCRs, it undergoes N-linked glycosylation, at Asn7 and Asn78,
within its N-terminal and EC1 domains, respectively, that inﬂuences
its membrane localisation, ligand binding and signalling [30,31].
Additionally, the hIP is somewhat unique among GPCRs in that it is
both isoprenylated and palmitoylated within its C-tail domain.
Farnesylation occurs in its distal C-tail domain at Cys383 within an
evolutionary conserved –CAAX motif [32], while it is palmitoylated at
three Cys residues (Cys308 , Cys309 and Cys311) in the proximal C-tail
adjacent to α-H8 (residues 297–307) of the hIP [33,34]. Together,
these dual lipidations are proposed to confer a double loop structure
through the formation of a fourth (IC4) and ﬁfth (IC5) IC loop within
the C-tail of the hIP and are required to maintain G protein coupling
and effector signalling [32,33]. Furthermore, it has recently been
established that both the mature, fully glycosylated (46–66 kDa) and
immature, non-glycosylated and core-glycosylated (38–44 kDa)
species of the hIP may be polyubiquitinated and that this is required
for lysosomal sorting of the mature, internalised receptors and for
degradation of the immature species by the 26S proteasomes through
the endoplasmic reticulum (ER)-associated degradation (ERAD)
process, respectively [35].
Members of the Rab GTPases participate at multiple steps in the
processing, maturation and intracellular trafﬁcking of several GPCRs
[36]. Most typically, Rab5a is present at the plasma membrane (PM)
and early endosomes and mediates early endosome trafﬁcking and
fusion while Rab4a and Rab11a are associated with early and late
recycling endosomes to regulate GPCR recycling through the so-called
short and long recycling pathways, respectively [37–40]. Through
recent studies, it has been established that the hIP undergoes agonist-
induced internalisation through a Rab5a-dependent mechanism [41]
and can be recycled to the PM through the “slow” recycling path
involving, somewhat unusually, a direct interaction between the hIP
and Rab11a [42]. Indeed, the structural determinants required for its
interaction with Rab11a have been determined and are localised to a
14-residue Rab11a binding domain (RBD) within the proximal C-tail
domain of the hIP comprised of Val299–Val307, corresponding to much
of its α-H8 domain, adjacent to the palmitoylation residues at Cys308–
Cys311 [34]. Furthermore, Ala-scanningmutagenesis of the 14-residue
RBD revealed that hydrophobic residues, namely Phe300, Leu303,
Leu305 and Val307, which mainly lie on one face of the α-H8 were
critical for the interaction with Rab11a. However, the fact that Ala-
scanning mutagenesis of two positively charged residues, namely
Arg302 and Lys304, withinα-H8 also disrupted the association between
the hIP and Rab11a residues was inconclusive with regard to RBD
function as the resultant mutated receptors (hIPR302A and hIPK304A)
did not display a normal pattern of maturation or expression at the
PM relative to the hIP itself [43].
While the molecular basis for the failure of the hIPR302A and
hIPK304A variants to mature and trafﬁc to the PM was unclear, it was
suggestive that these residues may possibly be part of an ER export
motif most typically located within the proximal C-tail domain of
many GPCRs [44,45]. Whilemany different or variant ER export motifs
have been identiﬁed, perhaps the highly conserved F(X)6LL motif,
proposed to be present in most, but not all, GPCRs, including the α1B-
adrenergic receptor (AR), α2B-AR, β2-AR and angiotensin II type 1A
receptor (AT1R), is the most prevalent and widely characterized
[46,47]. Members of the prostanoid receptor subfamily, including the
IP, are notable exceptions among GPCRs in that they do not contain
the F(X)6LL motif [15]. Hence, the aim of the current study was to
further investigate the molecular basis of the abnormal pattern of
expression of the hIPR302A and hIPK304A, aiming to identify the majorER export motif within the hIP. Owing to the fact that Ala-scanning
mutagenesis of the 14 residue RBD encompassing much of α-H8
revealed that mutation of Lys/Arg residues alone affected hIP
expression led us to investigate whether other positively charged
residues, such as within the C-tail domain of the hIP might also affect
its maturation and/or expression at the PM. The hIP contains ﬁve Lys
residues within its primary sequence where Lys218 is located in IC3
while, notably, Lys297, Lys304, Lys342 and Lys376 are located in the C-tail
domain (Fig. 1). Hence, the initial aim was to investigate the role of
Lys residues in the maturation and processing of the hIP and
thereafter to deﬁne the ER export motif(s). Results herein identify a
novel 8 amino acid ER export motif, K/R(X)4K/R(X)K/R, within α-H8
of the hIP deﬁned by a strict requirement for three positively charged,
basic Lys/Arg residues at the 1st, 6th and 8th positions, and represents
a motif that is evolutionarily conserved in the IP sequences of many
other species.
2. Materials and methods
2.1. Materials
Cicaprost was a gift from Bayer Schering Pharma AG. [3H]iloprost
(15.3 Ci/mmol) was from Amersham Biosciences. Fura2/AM and
epoxomicin were from Calbiochem. Fluo-4 was from Molecular
Probes. QuikChangeTM site-directed mutagenesis kit was from
Stratagene. Effectene® transfection reagent was from Qiagen. The
chemiluminescence western blotting kit and rat monoclonal 3F10
anti-HA antibody were from Roche. Mouse monoclonal anti-HA 101R
antibody (1 mg/ml) was from Cambridge Biosciences. Anti-calnexin
rabbit polyclonal antibody was from Bioquote. Horseradish peroxi-
dase (HRP)-conjugated goat anti-rat IgG and goat anti-rabbit IgG
antibodies were from Santa Cruz Biotechnology. AlexaFluor® 488 goat
anti-rabbit IgG and AlexaFluor® 594 goat anti-mouse IgG were from
Molecular Probes. DAPI and MG132 were obtained from Sigma. The
oligonucleotides used in these studies were synthesised by Sigma-
Genosys. The plasmid yellow ﬂuorescent protein (YFP)-1,4-β-galac-
tosyltransferase (YFP-β-Gal) [48] was a kind gift from Dr. Natalia Jura
(Stony Brook University Cold Spring Harbor Laboratory, NY, U.S.A.).
2.2. Site-directed mutagenesis of the hIP
The plasmid pHM6:hIPWT has been previously described [49]. The
plasmids pHM6:hIPK218Q, pHM6:hIPK297Q, pHM6:hIPK304Q, pHM6:
hIPK342Q, pHM6:hIPK376Q, pHM6:hIPK297,304Q, pHM6:hIPK342,376Q,
pHM6:h IPK 2 9 7 , 3 0 4 , 3 4 2Q , pHM6:h IPK2 9 7 , 3 0 4 , 3 7 6Q , pHM6:
hIPK297,304,342,376Q, pHM6:hIPK218,297,304,342,376Q, pHM6:hIPK297A,
pHM6:hIPK304A, pHM6:hIPK376A, pHM6:hIPK297,304A, pHM6:hIPA298G,
pHM6:hIPV299A, pHM6:hIPF300A, pHM6:hIPQ301A, pHM6:hIPR302A,
pHM6:hIPL303A, pHM6:hIPK297Q,R302L,K304Q, pHM6:hIPK297R, pHM6:
hIPR302K, pHM6:hIPK304R and pHM6:hIPK297,304R were generated
using the template and sense/antisense primer pairs as outlined in
Table 1. Site-directed mutagenesis was performed using the Quik-
ChangeTM system (Stratagene) and all plasmids were validated using
double-stranded DNA sequencing analysis.
2.3. Cell culture and establishment of stable cell lines
Human embryonic kidney (HEK) 293 cells, obtained from the
American Type Culture Collection, were cultured in minimum
essential medium (MEM), supplemented with 10% foetal bovine
serum (FBS).
The HEK.hIP cell line stably overexpressing a HA-tagged form of
the hIP has been previously described [49]. For the establishment of
the other recombinant HEK 293 stable cell lines used herein,
routinely, HEK 293 cells were plated at a density of 2×106 cells/
100-mm dish approximately 48 hr prior to transfection. Cells were
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Fig. 1. Schematic of the structural organisation of the hIP. The hIP is predicted to contain an amino (N)-terminal extracellular (EC) domain, seven hydrophobic transmembrane (TM)
α-helical domains (TM1-TM7) connected by 3 alternating intracellular (IC) loops (IC1–IC3) and 3 EC loops (EC1–EC3) and an IC carboxyl-terminal (C-tail) domain. It is also subject to a
number of post-translational modiﬁcations including N-linked glycosylation at Asn7 and Asn78 (represented by the sugar chains); palmitoylation at Cys308, Cys309 and Cys311 (red
triangles), and isoprenylation/farnesylation at Cys383 (blue diamond) which together may introduce a double loop structure by creating a fourth (IC4) and ﬁfth (IC5) IC loop within
the proximal and distal regions, respectively, of the C-tail domain of the hIP. The eighth α-helical domain (α-H8) comprising Lys297–Val307 adjacent to the palmitoylated residues at
Cys308–Cys311, lying perpendicular to the TM α-helices, is underlined. The hIP contains ﬁve Lys residues, Lys218 in IC3 and Lys297, Lys304, Lys342 and Lys376 in its C-tail domain (yellow
circles) while Arg302, between Lys297 and Lys304 in its proximal C-tail domain, is also highlighted (green square).
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plus 10 μg of ScaI-linearised pAdVA [50] using the CaCl2/DNA co-
precipitation procedure, as previously described [51]. Forty-eightTable 1
Templates and oligonucleotide primers used for site-directed mutagenesis of the hIP.
Plasmid Template
pHM6:hIPK218Q pHM6:hIPWT
pHM6:hIPK297Q pHM6:hIPWT
pHM6:hIPK304Q pHM6:hIPWT
pHM6:hIPK342Q pHM6:hIPWT
pHM6:hIPK376Q pHM6:hIPWT
pHM6:hIPK297,304Q pHM6:hIPWT
pHM6:hIPK342,376Q pHM6:hIPK376Q
pHM6:hIPK297,304,342Q pHM6:hIPK342Q
pHM6:hIPK297,304,376Q pHM6:hIPK376Q
pHM6:hIPK297,304,342,376Q pHM6:hIPK342,376Q
pHM6:hIPK218,297,304,342,376Q pHM6:hIPK297,304,342,376Q
pHM6:hIPK297A pHM6:hIPWT
pHM6:hIPK304A pHM6:hIPWT
pHM6:hIPK376A pHM6:hIPWT
pHM6:hIPK297,304A pHM6:hIPK304A
pHM6:hIPA298G pHM6:hIPWT
pHM6:hIPV299A pHM6:hIPWT
pHM6:hIPF300A pHM6:hIPWT
pHM6:hIPQ301A pHM6:hIPWT
pHM6:hIPR302A pHM6:hIPWT
pHM6:hIPL303A pHM6:hIPWT
pHM6:hIPK297Q,R302L,K304Q pHM6:hIPK297,304Q
pHM6:hIPK297R pHM6:hIPWT
pHM6:hIPR302K pHM6:hIPWT
pHM6:hIPK304R pHM6:hIPWT
pHM6:hIPK297,304R pHM6:hIPK297R
*Oligonucleotide sequences presented correspond to those of the sense primer only; the ant
the actual mutated base(s) underlined.hours post-transfection, G418 (0.8 mg/ml) selection was applied.
Individual G418-resistant colonies were selected after approximately
21 days and clonal cell lineswere expanded giving rise to the HEK.hIP-Oligonucleotide primer
5′-TACCCGCCAGGAGCAGCGCCACCAGGGC-3′
5′-CATCCTTTTCCGCCAGGCTGTCTTCCAGC-3′
5′-TTCCAGCGACTCCAGCTCTGGGTCTGC-3′
5′-GCTCCTGTGGGACAGGAGGGGAGCTGC-3′
5′-GTGGGAACGTCGTCCCAAGCAGAAGCCAG-3′
5′- GTCTTCATCCTTTTCCGCCAGGCTGTCTTCCAG
CGACTCCAGCTCTGGGTCTGCTG -3′
5′- GCTCCTGTGGGACAGGAGGGGAGCTGC -3′
5′- GTCTTCATCCTTTTCCGCCAGGCTGTCTTCCAGCG
ACTCCAGCTCTGGGTCTGCTG -3′
5′- GTCTTCATCCTTTTCCGCCAGGCTGTCTTCCAGCG
ACTCCAGCTCTGGGTCTGCTG -3′
5′- GTCTTCATCCTTTTCCGCCAGGCTGTCTTCCAGCG
ACTCCAGCTCTGGGTCTGCTG -3′
5′-TACCCGCCAGGAGCAGCGCCACCAGGGC-3′
5′-CTTCATCCTTTTCCGCGCGGCTGTCTTCCAGCGAC-3′
5′-GTCTTCCAGCGACTCGCGCTCTGGGTCTGCTGC-3′
5′-GTGGGAACGTCGTCCGCAGCAGAAGCCAG-3′
5′-CTTCATCCTTTTCCGCGCGGCTGTCTTCCAGCGAC-3′
5′-CCTTTTCCGCAAGGGCGTCTTCCAGCGAC-3′
5′-CCTTTTCCGCAAGGCTGCCTTCCAGCGACTCAAGC-3′
5′-CCGCAAGGCTGTCGCCCAGCGACTCAAGC-3′
5′-CGCAAGGCTGTCTTCGCGCGACTCAAGCTC-3′
5′-AAGGCTGTCTTCCAGGCACTCAAGCTCTGGGTC-3′
5′-GCTGTCTTCCAGCGAGCCAAGCTCTGGGTC-3′
5′-GCTGTCTTCCAGCTCCTCCAGCTCTGGGTC-3′
5′-CATCCTTTTCCGCAGGGCTGTCTTCCAGC-3′
5′-GCAAGGCTGTCTTCCAGAAACTCAAGCTCTGGGTCTG-3′
5′-CTTCCAGCGACTCAGGCTCTGGGTCTGCT-3′
5′-CTTCCAGCGACTCAGGCTCTGGGTCTGCT-3′
isense sequence is inferred. The identity of the mutator codon is in boldface italics with
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assayed by radioligand-binding assays, as outlined below.
2.4. Radioligand-binding assays
Radioligand-binding assays (RLBAs) of the IP were carried out as
previously described [52]. Brieﬂy, cells were harvested by centrifu-
gation at 500g at 4 °C for 5 min and washed three times with ice-cold
PBS. Following resuspension in Homogenisation Buffer (25 mM Tris/
HCl, pH 7.5; 0.25 M sucrose; 10 mM MgCl2; 1 mM EDTA; 0.1 mM
phenylmethylsulfonyl ﬂuoride (PMSF)), cells were homogenised and
centrifuged at 100,000g for 60 min at 4 °C. The pellet fractions (P100),
representing crude membranes, were resuspended in Resuspension
Buffer (10 mMMES/KOH, pH 6.0; 10 mMMnCl2; 1 mM EDTA; 10 mM
indomethacin). Protein determinations were carried out using the
Bradford assay [53]. RLBAs were carried out at 30 °C for 1 hr in a ﬁnal
assay volume of 100 μl using 35–100 μg of membrane P100 fraction/
assay in the presence of 4 nM [3H]iloprost (15.3 Ci/mmol), for
saturation binding studies, or in the presence of 0.1–200 nM [3H]
iloprost for Scatchard analysis. Nonspeciﬁc bindingwas determined in
the presence of 0.2 mM iloprost for saturation binding studies or in
the presence of 500-fold molar excess of nonlabeled iloprost for
Scatchard binding studies. Alternatively to analyse cell surface IP
expression, following harvesting and washing in PBS, cells were
resuspended in MES/KOH buffer and RLBAs were carried out at 4 °C
for 1 hr, using 35–100 μg of whole cell protein in 100 μl reactions in
the presence of 4 nM [3H]iloprost (15.3 Ci/mmol) as previously
described. Reactions were terminated by the addition of 4 ml of ice-
cold Resuspension Buffer followed by ﬁltration through Whatman
GF/C ﬁlters, which had been pretreated in 0.3% polyethyleneimine
(PEI) for 1–24 hr. The ﬁlters were washed three times with
Resuspension Buffer (4 ml) and radioactivity counted in scintillation
ﬂuid (5 ml/ﬁlter) using a Tri-Carb 2900TR Liquid Scintillation
Analyzer. Radioligand binding data were analyzed using the PRISM
5 computer program (GraphPad Software Inc., San Diego, CA) to
determine the Kd and Bmax values. The suitability of both one-site and
two-site binding models was examined using the F-test. The level of
signiﬁcance of the results of the F-test was tested to pb0.05.
2.5. Measurement of intracellular Ca2+ mobilisation
Measurement of intracellular Ca2+ ([Ca2+]i) mobilisation in Fura2/
AM-preloaded cells was carried out essentially as previously de-
scribed [51]. Brieﬂy, cells were harvested and washed three times in
ice-cold PBS. Cells were resuspended (1.6×106 cells/ml) in modiﬁed
Ca2+/Mg2+-free HBSSHB (Hanks’ buffered salt solution containing
20 mM HEPES, pH 7.67, 0.1% bovine serum albumin (BSA)) and were
loadedwith 5 μMFura2/AM for 40 min at 37 °C in the dark. Thereafter,
cells were harvested by centrifugation at 500g for 5 min at room
temperature (RT), washed once in HBSSHB and ﬁnally diluted to
0.8×106 cells/ml in HBSSHB containing 1 mM CaCl2. Cells (2 ml
aliquots) were then stimulated with cicaprost (1 μM) and Fura2
ﬂuorescence from gently stirred cells was recorded using a Perkin-
Elmer LS50-B spectroﬂuorometer at excitation wavelengths of
340 nM and 380 nM and an emission wavelength of 510 nm [54].
Alternatively, for determination of half maximal effective concentra-
tion (EC50) values, cells were harvested and washed thrice in Krebs/
HEPES buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 4.2 mM NaHCO3, 11.7 mM D-glucose, 1.3 mM CaCl2, 10 mM
HEPES, pH 7.4) prior to pre-loading with Fluo-4/AM (1 hr at 25 °C;
3 μM in Krebs/HEPES buffer containing 1% Pluoronic F-127). There-
after, cells were washed twice and resuspended (3×105 cells/ml) in
Krebs/HEPES buffer containing 0.5% BSA. Cells (0.18 ml aliquots) were
then stimulated with cicaprost (0.01 nM–5 μM) and Fluo-4 ﬂuores-
cence was recorded using a Fluoroskan Ascentmicroplate ﬂuorometer
at excitation wavelength of 485 nM and an emission wavelength of518 nm [55]. For each [Ca2+]i mobilisation, calibration of the
ﬂuorescence signal was performed in 0.2% Triton X-100 to obtain
the maximal ﬂuorescence (Rmax) and in 1 mM EGTA, to obtain the
minimal ﬂuorescence (Rmin). The ratio of the ﬂuorescence at 340 nM
to that at 380 nM in Fura2-loaded cells or ﬂuorescence at 518 nm
in Fluo-4-preloaded cells is a measure of [Ca2+]i mobilisation,
assuming a Kd of 225 nM or 345 nM Ca2+ for Fura2/AM or Fluo-4,
respectively. Data presented are representative of at least three
independent experiments and were calculated as mean changes in
intracellular Ca2+ mobilised (Δ[Ca2+]i±S.E.M., nM) as a function of
time (s) following ligand stimulation.
2.6. Immunoprecipitations, SDS-PAGE and western blotting
To examine expression of the HEK.hIP-based stable cell lines, cells
were seeded at 2×105 cells/well in 6-well plates and grown for 72–
96 hr. Thereafter, cells were harvested in 1× PBS, pH 7.4 containing
protease inhibitors (0.5 mM PMSF; 2.0 mM 1, 10 phenanthroline;
10 μg/ml aprotinin; 1 mM benzamidine hydrochloride; 1 μg/ml
leupeptin). In order to examine the effect of the proteasomal
inhibition on hIP expression, cells were incubated with MG132
(10 μM), epoxomicin (0.1 μM) or, as control, with vehicle (0.001%
DMSO) for 12 hr. In all cases, protein concentration was assayed using
the Bradford assay [53]. Generally, 50 μg total cellular protein was
resuspended in SDS-sample Buffer (10% β-mercaptoethanol (v/v); 2%
SDS (w/v); 30% glycerol (v/v); 50 mM Tris–HCl, pH 6.8; 0.025%
bromophenol blue (w/v)). Samples were then boiled for 10 min prior
to resolution by SDS-PAGE, on 10% polyacrylamide gels, followed by
electroblotting onto PVDF membrane. Blots were screened versus the
anti-HA (3F10; 1:1,000) antibody, followed by the secondary HRP-
conjugated goat anti-rat IgG antibody (1:5,000), and HA-tagged
proteins were visualised using the chemiluminescence detection
system, as described by the supplier. All blots illustrated in the ﬁgures
are representative blots from 3 to 6 experiments (n=3–6).
In order to examine the possible interaction of the ER chaperone
protein calnexin with the hIP, following harvesting and washing, cells
were lysed in radio-immunoprecipitation (RIP) Buffer (50 mM Tris–
HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40 (v/v), 0.5% sodium
deoxycholate (w/v), 0.1% SDS (w/v), 10 mM sodium ﬂuoride, 25 mM
sodium pyrophosphate) supplemented with protease inhibitors
(1 mM PMSF; 10 μg/ml aprotinin; 1 μg/ml leupeptin) and lysed by
sequentially passing through hypodermic needles of decreasing bore
size (18-, 21-, 23- and 26-gauge), as previously described [35]. HA-
tagged receptors from resulting supernatants (~600 μg) were immu-
noprecipitated with anti-HA (101R; 1 in 300) antibody at 4 °C for
16 hr, processed and analysed by SDS-PAGE, on 10% acrylamide gels,
and western blotting essentially as previously described [43]. Blots
were screened using the anti-calnexin and anti-HA (3 F10) antisera
followed by chemiluminescence detection.
2.7. Confocal microscopy
HEK.hIP-based cells were seeded onto coverslips, which were
pretreated with 0.1 mg/ml poly-L-lysine in 6-well plates, and grown
for 48 hr. Where indicated, cells were transiently transfected with the
plasmidYFP-β-Gal encoding theGolgimarker or, as control,with empty
vector using Effectene® transfection reagent, essentially as outlined by
the manufacturer (Qiagen). Forty-eight hr post-transfection, cells were
ﬁxed using 3.7% paraformaldehyde, 1× PBS, pH 7.4, for 15 min at RT and
thereafter washed three times with PBS. Cells were permeabilised by
incubation with 0.2% Triton X-100 in PBS for 10 min on ice, followed by
washingwith 1×TBS. Nonspeciﬁc siteswere blocked by incubating cells
with 1% BSA, 1× TBS, pH 7.4 for 1 hr at RT. Cells were incubated with
either the anti-HA 101R primary antibody (1:1,000 in 1% BSA) to label
the HA-tagged hIP receptors or the anti-calnexin primary antibody
(1:150 in 1% BSA) to label the ER for 1 hr at RT. The antibody solution
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further incubation with 1% BSA for 30 min. Cells were then incubated
with Alexa Fluor® 594 goat anti-mouse IgG secondary antibody
(1:4,000 in 1% BSA) to detect the HA-tagged receptors and/or Alexa
Fluor® 488 goat anti-rabbit IgG secondary antibody (1:4,000 in 1% BSA)
todetect theER for 1 hr at RT. Cellswerewashed twice in 1×TBSprior to
counterstaining of the nuclei with DAPI (1 μg/ml in H2O). Coverslips
were mounted onto glass slides using ﬂuorescent mounting medium
(Dako). Slideswere then imaged at ×63magniﬁcation using a Carl Zeiss
Laser Scanning System LSM510 and Zeiss LSM Imaging software.
2.8. Computational structure predictions
Structure prediction of the hIP, consistent with a previous report
[43], and of the variant hIPK297Q,R302L,K304Q or of the human β1
adrenergic receptor (h.β1AR; NP_000675) were generated by online
submission to the iterative TASSER (I-TASSER) algorithm, a three
dimensional structure prediction software that builds models based
on multiple-threading consensus target-to-template alignments by
LOM-ETS (Local Meta-Threading Server) and I-TASSER simulations
(available on the University of Michigan web site) [56,57]. I-TASSER
predictions were in agreement with those generated from indepen-
dent predictions using PHYRE (available on theWorldWideWeb) and
were further analysed for helical content using the AGADIR prediction
algorithm (available on the World Wide Web). Amphipathic helical
predictions were carried out using the online tool (available on the
World Wide Web). Jpred 3 [58], a web system of different secondary
structure prediction algorithms (see the University of Dundee web
site) was used to conﬁrm that mutations generated, such as by the
Ala-scanningmutagenesis, per se did not affect the formation of the α-
H8 domain.
2.9. Data analyses
Statistical analyses were carried out using the unpaired Stu-
dent's t-test or, where relevant and speciﬁcally indicated in the text,
using two-way ANOVA employing the GraphPad Prism package. P-
values of≤0.05 were considered to indicate a statistically signiﬁcant
difference.
3. Results
3.1. Role of lysines in inﬂuencing the expression and intracellular
signalling of the hIP
The human prostacyclin receptor (hIP) contains ﬁve Lys residues
where Lys218 is located in IC3 and the remaining 4 (Lys297, Lys304,
Lys342 and Lys376) are located in its C-tail domain (Fig. 1). Hence, the
initial aimwas to investigate the role of Lys residues in thematuration
and processing of the hIP. To this end, each of the ﬁve Lys residues
were mutated, either individually or in various combinations, by
semi-conservative substitution to corresponding Gln (Q) residues,
thereby minimising any potential non-speciﬁc mutational effects. In
all, cDNAs encoding 11 different ‘Lys to Gln’ variants of the hIP were
generated (Table 1) and clonal cell lines stably over-expressing
hemagglutinin (HA)-tagged forms of each receptor were established
inmammalian human embryonic kidney (HEK) 293 cells. Those stable
cell lines were characterised by western blot analysis to assess
receptor expression levels and, functionally, by radioligand binding
assays (RLBAs) and by assessment of agonist-induced intracellular
calcium ([Ca2+]i) mobilisation, where data throughout were com-
pared to the previously characterised HEK.hIP cell line expressing a
HA-tagged form of the wild type hIP [49].
Consistent with a previous report [35], western blot analysis of
whole cell protein from HEK.hIP cells showed that the hIP is
predominantly expressed as a mature, fully glycosylated species(46–66 kDa) and as an immature, core glycosylated, non-farnesylated
intermediate species detected at~44 kDa (Fig. 2A) while the lesser
abundant immature, core glycosylated, farnesylated intermediate
species, detected at ~42 kDa, is only evident following prolonged
exposure of the immunoblots (data not shown). No expression of
HA-tagged protein was detected in the control HEK 293 cell line
(Fig. 2A). The overall pattern of expression of hIPK218Q and hIPK376Q
was, in effect, identical to that of the wild-type hIP (Fig. 2A).While the
hIPK342Q and hIPK342,376Q (Fig. 2A) showed signiﬁcant expression of
both core glycosylated intermediates (44 and 42 kDa) and the fully
mature, glycosylated species (46–66 kDa), their overall migration
patterns were somewhat slower than those of the hIP and hIPK376Q.
The reason for this altered migration is unknown, but suggests that
mutation of Lys342 alters the pattern of glycosylation of the hIP. In the
case of the hIPK297Q and hIPK304Q, both of these receptor variants were
almost exclusively expressed as the immature core glycosylated
intermediate (44 kDa), while the levels of their mature, fully
glycosylated species were barely detectable (Fig. 2A, compare
hIPK297Q and hIPK304Q to the hIP). Longer exposure of the immunoblot
was required to detect the 42 kDa species (data not shown). Analysis
of whole cell protein from HEK.hIPK297,304Q cells (Fig. 2A) also
demonstrated that the hIPK297,304Q is predominantly expressed as
the core glycosylated 44 and 42 kDa intermediates with almost a
complete absence of the mature, fully glycosylated species. Addition-
ally, and consistent with this, the hIPK297,304,342Q, hIPK297,304,376Q,
hIPK297,304,342,376Q and hIPK218,297,304,342,376Q were also predominantly
expressed as the core glycosylated 44 and 42 kDa intermediates
(Fig. 2A). Therefore, the presence of Lys297 and/or Lys304 appears to be
essential for complete glycosylation and maturation of the hIP.
RLBAs, using crude (P100) membrane fractions and employing [3H]
iloprost as selective radioligand, established that the level of hIP
expression in HEK.hIP cells was typically 1.55±0.25 pmol/mg
membrane protein (Fig. 2B). There was no signiﬁcant difference in
[3H]iloprost binding by the hIPK218Q, hIPK342Q, hIPK376Q or hIPK342,376Q
receptors relative to that of the wild-type hIP (Fig. 2B). However,
radioligand binding by the hIPK297Q and hIPK304Q were reduced by
74.8% and 54.2%, respectively, compared to the hIP (Fig. 2B, pb0.01
and pb0.05, respectively), while that of hIPK297,304Q was reduced by
83.9% (Fig. 2B, pb0.01). Additionally, [3H]iloprost binding by the
hIPK297 ,304 ,342Q, hIPK297 ,304 ,376Q, hIPK297 ,304 ,342 ,376Q and
hIPK218,297,304,342,376Q were signiﬁcantly reduced compared to the
hIP (Fig. 2B, pb0.01 in each case). Collectively, RLBA data conﬁrmed
that all variant hIPs carrying the ‘Lys297 to Gln297’ or ‘Lys304 to Gln304’
mutations, either alone or in combination with any of the other ‘Lys to
Gln’ mutations displayed impaired [3H]iloprost binding relative to the
wild-type hIP and correlated well with observations from western
blotting data (Fig. 2A).
In order to assess whether the alteration in ligand binding by the
‘Lys297 to Gln297’ or ‘Lys304 to Gln304’ variants is actually due to
alterations in receptor expression at the cell surface, RLBAs were also
carried out on whole cells by incubation with [3H]iloprost at 4 °C.
Consistent with previous studies [33], incubation with [3H]iloprost at
4 °C, as opposed to at 30 °C, inhibits agonist-induced internalisation of
the hIP, allowing for more accurate measurement of the cell surface
expression of the hIP using whole cells as opposed to using crude
membrane preparations present in P100 fractions. Using this approach,
levels of hIP expression in HEK.hIP cells were typically 1.93±0.06
pmol/mg whole cell protein (Fig. 2C) and there was no substantial
difference in the level of expression of the hIPK218Q, hIPK342Q or
hIPK376Q at the cell surface relative to the hIP. In contrast, expression
of both the hIPK297Q and hIPK304Q were reduced by 69.9% and 62.7%,
respectively, compared to the hIP (Fig. 2C, pb0.05 in each case), while
that of hIPK297,304Q was reduced by 90.3% (Fig. 2C, pb0.005).
Moreover, Scatchard analyses determined that there were no
substantial differences in the afﬁnity constant (Kd) at either the
high or low afﬁnity binding sites of any of the ‘Lys to Gln’ variants
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gand binding data (Fig. 2B and C), there was substantial variations in
the Bmax values in variants carrying ‘Lys297 to Gln297’ or ‘Lys304 to Gln304’
mutations at both the high and low afﬁnity binding sites but at levels
entirely reﬂective of those in Fig. 2B and C (data not shown).
The consequence of the ‘Lys to Gln’ mutations on functional hIP
expression was also examined by analysis of agonist-induced [Ca2+]i
mobilisation in response to stimulation of the HEK 293 clonal cell lines
with the highly selective IP agonist cicaprost. Stimulation of HEK.hIP
cells generated a large transient rise in [Ca2+]i mobilisation in response
to cicaprostwhichwas signiﬁcantly greater than that of the control HEK
293 cell line (Fig. 2D; compare 20.1±3.7 nM versus 141.2±5.8 nM,
pb0.001). Levels of [Ca2+]i mobilised by the hIPK218Q, hIPK342Q, hIPK376Q
or hIPK342,376Q were not signiﬁcantly different to the hIP (Fig. 2D).
Hence, while the hIPK342Q and hIPK342,376Q exhibit slightly modiﬁed
patterns of glycosylation compared towild-type hIP, this does not affect
their ability to bind radioligand or to mobilise [Ca2+]i in response to
agonist-stimulation. In contrast, levels of [Ca2+]i mobilisation by the
hIPK297Q and hIPK304Q were reduced by 62.7% and 44.4%, respectively,
compared to the hIP (Fig. 2D, pb0.001 and pb0.01, respectively).
Furthermore, levels of cicaprost-induced [Ca2+]i mobilisation by the
hIPK297,304Q, hIPK297,304,342Q, hIPK297,304,376Q, hIPK297,304,342,376Q and
hIPK218,297,304,342,376Q were reduced by 52.1%, 54.3%, 49.4%, 61.5% and
68.8%, respectively, compared to the hIP (Fig. 2D, pb0.001 in each case).
Furthermore, despite such differences in overall levels of [Ca2+]i
mobilised, concentration -response studies established that EC50 values
for cicaprost-induced [Ca2+]i mobilisation by any of the ‘Lys to Gln’
variants studiedwere not substantially different to that of the wild typeFig. 2. Effect of mutation of the ‘Lys to Gln’ residues on the expression and localisation of the hI
stably expressing HA-tagged hIPWT or variant receptors, as indicated, were resolved by SDS-PA
detection. The relative positions of the molecular size markers (kDa) are indicated between th
binding assays were performed on crude membrane (P100) fractions (B) or whole cells (C) fro
respectively, where data are presented asmean [3H]iloprost bound (pmol/mgprotein±S.E.M.,
cell types indicated with 1 μM cicaprost, where data are presented as mean maximal change
***pb0.001 indicates that themean level of [3H]iloprost bound (pmol/mgprotein) or themeanΔ
the wild-type hIP, where applicable. E. HEK.hIPWT, HEK.hIPK218Q, HEK.hIPK342,376Q, HEK.hIPK2
pcDNA3 empty vector (left panels) or with plasmid encoding the Golgi marker YFP-β-Gal (righ
HA 101R/Alexa Fluor® 594 goat anti-mouse IgG, calnexinwith anti-calnexin/Alexa Fluor® 488 g
(YFP) expression. In all cases, anti-HA, anti-calnexin, YFP or overlay images were captured, at ×
software. Data presented are representative images from 3 independent experiments from whhIP, including those variants carrying the ‘Lys297 to Gln297’ or ‘Lys304 to
Gln304’, either alone or in combination with other mutated Lys residues
(Table 3). More speciﬁcally, those EC50 values ranged between ~10 and
30 nM and any variations from that of the wild type hIP were not
exclusively attributable to those variants carrying the ‘Lys297 to Gln297’ or
‘Lys304 to Gln304’ mutations (Table 3). Collectively, these data correlate
well with previous western blotting and RLBA data and conﬁrm that all
hIP variants carrying the ‘Lys297 to Gln297’ or ‘Lys304 to Gln304’ mutations,
either alone or in any combination, are functionally defective whereby
they do not efﬁciently trafﬁc to the plasmamembrane (PM) and display
substantially reduced ligand binding and agonist-induced [Ca2+]i
mobilisation (Fig. 2A–D).
The signiﬁcant reductions in the relative expression of the 46–
66 kDa species of the hIP variants carrying the ‘Lys297 to Gln297’ or ‘Lys304
to Gln304’ mutations, coupled to their diminished functional expression
suggested that those receptors had impaired maturation to their fully
glycosylated forms and/or were unable to efﬁciently trafﬁc to the PM.
Hence, confocal image analysis was used to investigate the subcellular
localisation of the hIP and each of the ‘Lys to Gln’ variants expressed in
the respective clonal cell lines (Fig. 2E). More speciﬁcally, it was sought
to investigate whether thematuration and/or intracellular trafﬁcking of
the hIPK297Q, hIPK304Q and hIPK218,297,304,342,376Q may be disrupted,
resulting in their accumulation in the ER and/or the Golgi complex. To
locate the ER, cells were stained with an antibody directed to the ER
marker protein calnexin. The ER appears as a dense, reticular network in
HEK 293 cells, with particularly strong staining around the nuclear
envelope. To locate the Golgi, cells were cotransfected with an
expression plasmid encoding YFP-β-gal, a recombinant Golgi-complexP. A. Aliquots (50 μg) of whole cell protein from HEK 293 cells or clonal HEK 293 cell lines
GE and immunoblotted versus anti-HA (3F10) antibody followed by chemiluminescence
e panels. Data are representative of three independent experiments. B and C. Radioligand
m the cell types indicated, in the presence of 4 nM [3H]iloprost at 30 °C or 4 °C for 1 hr,
n=4). D. Agonist-induced intracellular Ca2+mobilisation in response to stimulation of the
s in intracellular Ca2+ mobilised (Δ[Ca2+]i±S.E.M., n=4). B–D. *pb0.05; **pb0.01; and
[Ca2+]i±S.E.M. by the variousmutant cell lineswas signiﬁcantly reduced in comparison to
97Q, HEK.hIPK304Q and HEK.hIPK218,297,304,342,376Q cells were transiently transfected with
t panels). Cells were ﬁxed and permeabilised prior to detection of HA-tagged IPs with anti-
oat anti-rabbit IgG primary/secondary antibodies, or enhanced yellow ﬂuorescent protein
63magniﬁcation, using a Carl Zeiss Laser Scanning System LSM510 and Zeiss LSM Imaging
ich at least 10 ﬁelds were viewed. The white horizontal bar represents 10 μm.
Fig. 2 (continued).
Table 2
Radioligand binding properties of hIPWT or the ‘Lys to Gln’ variants expressed in HEK
293 cells.
Receptor High afﬁnity site Low afﬁnity site
Kd
a Kd
a
hIPWT 3.60±0.23 25.3±4.45
hIPK218Q 2.03±0.40 15.4±1.65
hIPK297Q 2.45±0.35 9.11±1.19
hIPK304Q 3.90±0.23 8.32±0.57
hIPK342Q 3.58±0.67 36.6±0.89
hIPK376Q 2.21±0.63 39.7±5.37
hIPK218,297,304,342,376Q 2.31±0.91 12.7±4.44
Scatchard analysis was performed on membrane fractions of HEK 293 cells stably
transfected with the human prostacyclin receptor (hIP) or ‘Lys to Gln’ variants. Data are
presented as the means±S.E.M. (n≥3). The suitability of the two afﬁnity state binding
model was determined using the F-test to a signiﬁcance of 0.05.
a nM iloprost.
Table 3
Determination of EC50 values for Cicaprost-induced [Ca2+]i mobilisation.
Receptor EC50 value for Cicaprost-induced
[Ca2+]i a (nM±S.E.M.)
hIPWT 8.35±1.14
hIPK218Q 18.9±4.41
hIPK297Q 30.3±5.21
hIPK304Q 7.59±1.70
hIPK342Q 21.5±5.97
hIPK376Q 21.3±3.82
hIPK297,304Q 30.8±5.50
hIPK297,304,342Q 7.97±1.85
hIPK297,304,376Q 13.6±2.87
hIPK297,304,342,376Q 12.2±2.82
hIPK218,297,304,342,376Q 11.0±2.90
a EC50 values for cicaprost-induced [Ca2+]i mobilisation by hIPWT or the ‘Lys to Gln’
variants were determined in cells pre-loaded with Fluo-4. Data are presented as the
mean changes in [Ca2+]i±S.E.M. (n≥3).
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Fig. 3. Effect of mutation of the ‘Lys to Gln’ on degradation of the hIP through ERAD and
interaction with the ER chaperone Calnexin. A. HEK.hIPWT, HEK.hIPK297,304Q and HEK.
hIPK218,297,304,342,376Q cells were treated with 10 μM MG132, 0.1 μM Epoxomicin or as
control, vehicle for 12 hr. Whole cell proteins (50 μg) were resolved by SDS-PAGE
followed by immunoblotting versus anti-HA (3F10) antibody. B. HA-tagged receptors
were immunoprecipitated from HEK 293 cells, clonal HEK 293 cell lines stably
expressing HA-tagged hIPWT or mutated hIP variants, as indicated. Immunoprecipitates
(IP) were resolved by SDS-PAGE and immunoblotted (IB) versus anti-calnexin and anti-
HA (3F10) antibodies followed by chemiluminescence detection. The relative positions
of the molecular size markers (kDa) are indicated to the left of the panels. Data are
representative of three independent experiments.
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green ﬂuorescent protein fused to the trans-medial Golgi membrane-
anchoring signal peptide of human β-1,4-galactosyltransferase [48].
The HA-tagged hIP was mainly expressed at the PM in HEK.hIP
cells with relatively little intracellular localisation (Fig. 2E, anti-HA)
and no colocalisation with either calnexin or YFP-β-gal apparent in
these cells (Fig. 2E, anti-Calnexin, YFP-β-gal and Overlay panels).
Consistent with this, each of the single hIPK218Q, hIPK342Q, hIPK376Q and
double hIPK342,376Q mutated receptors, which bound radioligand and
mobilised [Ca2+]i in a manner similar to the wild-type hIP, were
mainly expressed at the PM and did not colocalise with the ER or Golgi
markers (Fig. 2E, data are presented for HEK.hIPK218Q and HEK.
hIPK342,376Q cells only). In contrast, the staining pattern detected in
cells expressing the hIPK297Q, hIPK304Q, hIPK297,304Q, hIPK297,304,342Q,
hIPK297,304,376Q, hIPK297,304,342,376Q and hIPK218,297,304,342,376Q receptors
was signiﬁcantly different from the wild-type hIP (Fig. 2E, where data
are presented for HEK.hIPK297Q, HEK.hIPK304Q and HEK.
hIPK218,297,304,342,376Q cells only). Both hIPK297Q and hIPK304Q exhibited
very poor expression at the PM, mainly showing a diffuse cytoplasmic
staining (Fig. 2E, anti-HA). Furthermore, both the hIPK297Q and
hIPK304Q strongly colocalised with the ER marker calnexin, but not
with the Golgi marker YFP-β-Gal (Fig. 2E, Overlay). In certain cell
ﬁelds, a small fraction of the cellular pool of the hIPK297Q and hIPK304Q
were capable of trafﬁcking to the PM (for example, see Fig. 2E, anti-
HA). This correlated well with western blotting data which indicated
that a small proportion of the hIPK297Q and hIPK304Q were detected as
the fully glycosylated, mature species (Fig. 2A). In the case of the
hIPK218,297,304,342,376Q, devoid of all Lys residues, it was unable to
trafﬁc to the PM (Fig. 2E, anti-HA), and showed strong co-localisation
with calnexin but not with YFP-β-Gal . Moreover, the
hIPK218,297,304,342,376Q strongly colocalised with the ER, but not with
the Golgi complex marker (Fig. 2E, Overlay panels). Combined, these
data suggest that any variant hIPs possessing either the ‘Lys297 to
Gln297’ or ‘Lys304 to Gln304’ mutations, either alone or in any
combination, were not expressed at or exported to the PM, being
retained in the ER compartment of the cell. Therefore, mutation of
Lys297 and/or Lys304 disrupts the normal anterograde transport of the
hIP from its site of synthesis in the ER through to the Golgi complex,
where ﬁnal post-translational modiﬁcation including end-stage
glycosylation occurs, before the receptor is transported to its
functional site at the PM.
3.2. Investigation of the turnover of the hIP through ERAD and
interaction with the ER chaperone calnexin
As previously stated, we have recently established that immature
species of the hIP are degraded through ERAD involving the ubiquitin-
dependent 26S proteasomal pathway while turnover of the mature,
fully glycosylated receptor mainly occurs through the lysosomal
pathway [35]. While the observed effects resulting from the
mutational studies herein of ‘Lys297 to Gln297’ or ‘Lys304 to Gln304’,
either alone or in combination with the other Lys218, Lys342 or Lys376
residues, may occur due to disruption of residues within a putative ER
export motif(s), another explanation may be that they occur either
due to (i) increased degradation of their immature forms through
ERAD and/or (ii) their misfolding due to altered association with ER
resident chaperone proteins such as calnexin. Hence, to address the
ﬁrst of these possibilities, (i) we examined the effect of the 26S
proteasomal inhibitors MG132 and/or epoxomicin on the expression
of the hIP and of its variants carrying the ‘Lys297 to Gln297’ or ‘Lys304 to
Gln304’ mutations (Fig. 3A and Supplemental Figure S1). Consistent
with previous reports [35], preincubation of HEK.hIP cells with
MG132 and/or epoxomicin led to accumulation of 4 immature species
of the hIP (38–44 kDa) but had no effect on the level of expression of
the fully glycosylated mature species (~ 44-66 kDa; Fig. 3A and
Supplemental Figure S1). Similarly, preincubation of cells expressingeither the hIPK297Q, hIPK304Q, hIPK297,304Q and hIPK218,297,304,342,376Q,
which are each exclusively expressed as the core glycosylated 44 and
42 kDa intermediates with almost a complete absence of the mature,
fully glycosylated species, with MG132 and/or epoxomicin also led to
accumulation of the 4 immature species of the hIP (38–44 kDa) and at
levels similar to those of the wild type hIP (Fig. 3A and Supplemental
Figure S1). Hence, these data are consistent with the previous study
that established that the hIP is subject to degradation through the
ERAD system [35] and, more speciﬁcally, that this occurs irrespective
of whether it is the wild type hIP or mutated variants containing the
K297Q or K304Q mutations.
To address the possibility that the hIP variants carrying the ‘Lys297
to Gln297’ or ‘Lys304 to Gln304’, either alone or in combination with the
other Lys218, Lys342 or Lys376 residues, may display reduced trafﬁcking
and functional expression at the PM due to (ii) possible altered
association with ER chaperones, the interaction of the hIP and ‘Lys to
Gln’ variants with endogenous calnexin was investigated through co-
immunoprecipitation studies (Fig. 3B). Calnexin was associated with
each of the anti-HA immunoprecipitates from the respective clonal
HEK 293 cells over-expressing HA- tagged forms of the hIPWT,
h IPK2 1 8Q , h IPK2 9 7Q , h IPK3 0 4Q , h IPK3 4 2Q , h IPK3 7 6Q and
hIPK218,297,304,342,376Q but was not present in corresponding anti-HA
immune complexes from the control HEK 293 cells (Fig. 3B). Hence,
collectively, these data establish that the effects of the ‘Lys to Gln’
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ERAD or in their folding status per se relative to that of the wild type
hIP but rather, more speciﬁcally, are consistent with the suggestion
that the ‘Lys297 to Gln297’ or ‘Lys304 to Gln304’ mutations disrupt a
putative ER export motif within the hIP.3.3. Effect of mutation of ‘Lys297 to Ala297’ and ‘Lys304 to Ala304’ on
expression, intracellular signalling and subcellular localisation of the hIP
To exclude the possibility that the observed altered maturation and
functional expression of the hIPK297Q and hIPK304Qmay be an artefact of
the choiceof ‘Lys297 toGln297’or ‘Lys304 toGln304’ substitutions, additional
mutational analysis was carried out whereby Lys297 and Lys304 were
mutated, either individually or in combination, to corresponding Ala
residues, with subsequent characterisation of the respective clonal HEK
293 cell lines (Table 1 and Fig. 4), as previous. As an additional controlFig. 4. Effect of mutation of the ‘Lys to Gln’ residues on the expression and localisation of the h
lines stably expressing HA-tagged hIP or hIP variants, as indicated. The relative positions of t
representative of three independent experiments. B. Radioligand binding assays were perfor
nM [3H]iloprost at 30 °C for 1 hr, where data are presented as mean [3H]iloprost bound (p
response to stimulation of cells with 1 μM cicaprost, where data are presented as meanmaxi
and ***pb0.001 indicates that the mean level of [3H]iloprost bound (pmol/mg protein) or th
comparison to the wild-type hIP, where applicable. D. HEK.hIP, HEK.hIPK376A, HEK.hIPK297A, H
HA-tagged IPs with anti-HA 101R/Alexa Fluor® 594 goat anti-mouse IgG or calnexin with an
(single or overlay) were captured at ×63 magniﬁcation using a Carl Zeiss Laser Scanning Sys
from 3 independent experiments from which at least 10 ﬁelds were viewed. The white horfor these studies, the consequence of mutation of Lys376 to Ala376 by
generating the hIPK376A variant was also investigated.
The hIP and the hIPK376A were expressed as the mature, fully
glycosylated species (46–66 kDa), with the core glycosylated interme-
diate species detected at~44 kDa and 42 kDa (Fig. 4A). The hIPK297A,
hIPK304A and hIPK297,304A were almost exclusively expressed as the core
glycosylated intermediates (44 and 42 kDa), with very little expression
of the mature, fully glycosylated receptors in any case (Fig. 4A). This
pattern of protein expression by hIPK297A, hIPK304A and hIPK297,304A was,
in effect, identical to that of hIPK297Q, hIPK304Q and hIPK297,304Q (Fig. 2A),
thereby verifying that the lack of mature, fully glycosylated species
associated with mutation of either Lys297 or Lys304 residues was not an
artefact of the nature of the mutation, be it a Gln or Ala, per se.
Assessment of [3H]iloprost binding conﬁrmed that radioligand
binding by the hIPK297A, hIPK304A and hIPK297,304A was signiﬁcantly
impaired (Fig. 4B, pb0.01), while that of the control hIPK376A was
almost identical to the wild type hIP. Furthermore, consistent withIP. A.Western blot analysis (50 μg) of whole cell protein fromHEK 293 cells or clonal cell
he molecular size markers (kDa) are indicated to the left of the blots. Data presented are
med on crude membrane (P100) fractions from cell types indicated in the presence of 4
mol/mg protein±S.E.M., n=4). C. Agonist-induced intracellular Ca2+ mobilisation in
mal changes in intracellular Ca2+mobilised (Δ[Ca2+]i±S.E.M., n=4). B and C. **pb0.01
e mean Δ[Ca2+]i±S.E.M. by the various mutant cell lines was signiﬁcantly reduced in
EK.hIPK304A or HEK.hIPK297,304A cells were ﬁxed and permeabilised prior to detection of
ti-calnexin/Alexa Fluor® 488 goat anti-rabbit IgG primary/secondary antibodies. Images
tem LSM510 and Zeiss LSM Imaging software. Data presented are representative images
izontal bar represents 10 μm.
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mobilisation by hIPK297A, hIPK304A and hIPK297,304A, but not that by
the hIPK376A, was signiﬁcantly reduced compared to the hIP (Fig. 4C,
pb0.001). Analysis of the subcellular distribution by immunoﬂuores-
cence microscopy revealed that while the hIP and hIPK376A were each
mainly expressed at the PM and did not co-localise with calnexin
(Fig. 4D), the hIPK297A, hIPK304A and hIPK297,304A showed intracellular
expression, with marked colocalisation with the ER marker calnexin
(Fig. 4D). The lack of cell surface expression of hIPK297A, hIPK304A and
hIPK297,304A is consistent with the previous imaging data for the ‘Lys297
to Gln297’ or ‘Lys304 to Gln304’ substitutions (Fig. 2E). Therefore, these
data conﬁrm that mutation of Lys297 and/or Lys304 to corresponding
Gln or Ala residues results in the failure of the hIP to be exported
from the ER to the Golgi complex and to undergo full end-stage
glycosylation and maturation with subsequent expression at the PM.
3.4. Ala-scanning mutagenesis of Lys297–Lys304 to identify critical
residues required for the export of the hIP from the ER
Lys297 and Lys304, established as key residues required for the
transport of the hIP from the ER to the PM (Figs. 2 and 4), are located
within α-H8 of the hIP, the domain located within its proximal C-tailFig. 5. Effect ofAla-scanningmutagenesis of Lys297–Lys304 on theexpression and localisation of th
the mutations generated are listed. In all cases, Ala-scanningmutagenesis was performed with
B. Western blot analysis (50 μg) of whole cell protein from HEK 293 cells or clonal cell lines s
molecular sizemarkers (kDa) are indicated between the blots. Data presented are representative
membrane (P100) fractions from the cell types indicated in the presence of 4 nM [3H]iloprost at 3
M., n=4). D. Agonist-induced intracellular Ca2+ mobilisation in response to stimulation of the
intracellular Ca2+mobilised (Δ[Ca2+]i±S.E.M.,n=4). C andD. **pb0.01 and ***pb0.001 indicat
M. by the variousmutant cell lines was signiﬁcantly reduced in comparison to thewild-type hIP
HA-tagged IPs with anti-HA 101R/Alexa Fluor® 594 goat anti-mouse IgG or calnexin with anti-c
Images (single or overlay)were captured at ×63magniﬁcation using a Carl Zeiss Laser Scanning
from 3 independent experiments from which at least 10 ﬁelds were viewed. The white horizonand predicted to span Lys297–Val307 adjacent to the palmitoylated
Cys308–Cys311 residues (Fig. 1). In order to determine if any other
residues within α-H8 may be required for the cell surface expression
and/or maturation of the hIP, Ala-scanning mutagenesis was
performed whereby each residue from Lys297–Lys304 was individually
substituted with Ala, except in the case of Ala298 which was mutated
to the alternative neutral residue Gly298 in that position (Fig. 5A).
Similar to the wild-type hIP, hIPA298G, hIPV299A, hIPF300A, hIPQ301A
and hIPL303A were each expressed in their respective clonal HEK
293 stable cell lines as the mature, fully glycosylated species
(46–66 kDa) and as the core glycosylated intermediate species
at~44 kDa and 42 kDa (Fig. 5B). The migration pattern of the mature
species of hIPL303A (Fig. 5B) was somewhat faster than that of the
hIP, suggesting that mutation of Leu303 may alter the pattern of
glycosylation of the hIP. Consistent with previous data (Fig. 4A),
hIPK297A and hIPK304A were mainly expressed as the core glycosy-
lated intermediate species (Fig. 5B). Strikingly, the hIPR302A was also
mainly expressed as the immature core glycosylated intermediates,
with very limited expression of the mature 46–66 kDa species
evident (Fig. 5B). These data suggest that Arg302, in addition to
Lys297 and Lys304, was absolutely required for complete glycosyla-
tion and maturation of the hIP.ehIP. A. The sequence of theα-H8 region, fromLys297 to Lys304, ofwild type hIP is givenand
the exception of Ala298 which was mutated to Gly298 at that position, to generate hIPA298G.
tably expressing HA-tagged hIP or hIP variants, as indicated. The relative positions of the
of three independent experiments. C. Radioligand binding assayswere performed on crude
0 °C for 1 hr,where data are presented asmean [3H]iloprost bound (pmol/mg protein±S.E.
cell indicated with 1 μM cicaprost, where data are presented as mean maximal changes in
es that themean level of [3H]iloprost bound (pmol/mg protein) or themeanΔ[Ca2+]i±S.E.
, where applicable. E. HEK.hIPR302A cells were ﬁxed and permeabilised prior to detection of
alnexin/Alexa Fluor® 488 goat anti-rabbit IgG primary/secondary antibodies, respectively.
System LSM510 and Zeiss LSM Imaging software. Data presented are representative images
tal bar represents 10 μm.
1212 P.D. Donnellan et al. / Biochimica et Biophysica Acta 1808 (2011) 1202–1218Levels of [3H]iloprost binding and cicaprost-induced [Ca2+]i
mobilisation by hIPA298G, hIPV299A, hIPF300A, hIPQ301A and hIPL303A
were modestly reduced in comparison to that of the hIP, but these
reductions were not found to be signiﬁcant (Fig. 5C and D). On the
other hand, and consistent with western blot analysis (Fig. 5B) and
previous data (Fig. 4), both [3H]iloprost binding and cicaprost-
induced [Ca2+]i mobilisation by hIPK297A, hIPR302A and hIPK304A cells
were signiﬁcantly reduced compared to the hIP (Fig. 5C, pb0.01 and
Fig. 5D, pb0.001, respectively). Moreover, confocal imaging con-
ﬁrmed that, similar to the wild type hIP, each of the hIPA298G, hIPV299A,
hIPF300A, hIPQ301A or hIPL303A were mainly expressed at the PM (data
not shown). Conversely, the hIPR302A (Fig. 5E) displayed a similar
pattern of expression to that of hIPK297Q, hIPK304Q, hIPK297A or hIPK304A
(Figs. 2E and 4D) in that it was not expressed at the PM but rather
exhibited diffuse intracellular staining and extensive co-localisation(A)
(B)
TM7
F295
L39
(i)
β
390L
Fig. 6. Effect of introducing the 'F(X)6LL’ ER export motif on the expression of the hIPK297,304Q.
372–381), hIP (residues 295–304) and its mutated variants, hIPK297,304Q and hIPK297Q,R302L,K304
(X)6LL ER export motif of the β1-AR and within the sequence of the hIPK297Q,R302L,K304Q varia
(ii) hIPK297Q,R302L,K304Q predict that they contain 7 TM, typical of their GPCR structure, and tha
(ii) lie within the proximal C-tail domains, organised into the eighthα-helical domain (α-H8)
the region including and surrounding theα-H8 domain of the hIPK297Q,R302L,K304Q is shown in (ii
navy blue in (i) and (ii). C.Western blot analysis (50 μg) of whole cell protein fromHEK 293 ce
The relative positions of the molecular size markers (kDa) are indicated to the left of the blo
binding assayswere performed on crudemembrane (P100) fractions from cell types indicated in
iloprost bound (pmol/mg protein±S.E.M., n=4). E. Agonist-induced intracellular Ca2+mobilis
presented as mean maximal changes in intracellular Ca2+ mobilised (Δ[Ca2+]i±S.E.M., n=
bound (pmol/mg protein) or the mean Δ[Ca2+]i±S.E.M. by the various mutant cell lines w
hIPK297Q,R302L,K304Q cells were ﬁxed and permeabilised prior to detection of HA-tagged IPs with
Fluor® 488 goat anti-rabbit IgG primary/secondary antibodies, respectively. Images (single o
LSM510 and Zeiss LSM Imaging software. Data presented are a representative image from3 ind
represents 10 μm.with calnexin (Fig. 5E). Collectively, these data suggest that Lys297,
Arg302 and Lys304 are speciﬁcally required for the export of the hIP
from the ER and subsequent maturation and trafﬁcking to the PM.
3.5. Effect of introducing the ‘F(X)6LL’ ER export motif on expression and
signalling by hIPK297,304Q
The sequence ‘F(X)6LL’, where F is Phe, X is any amino acid and L is
Leu or Ile, has been identiﬁed as an ER export motif located within the
proximal C-tail domains of many GPCRs including that of the α2B-AR,
β1-AR and AT1R [46,47].While this somewhat canonical F(X)6LLmotif
is not found in the primary sequence of any of the 8 members of the
prostanoid receptor subfamily of GPCRs, including of the hIP,
alignment of the sequences of the hIP and the β1-AR reveals a marked
similarity in this region except that the critical diLeu of the ‘F(X)6LL’ isF295
TM7
1
(ii)
302
303
L
L
A. The amino acid sequence of the proximal C-tail domains of the human β1-AR (residues
Q, are shown. The core Phe (F) and dileucine (LL) residues located within the canonical F
nt are underlined. B. I-TASSER three-dimensional structural analyses of the (i) β1AR and
t the F383(X)6L390L391 motif of β1AR (i; inset) and F295(X)6L302L303 of hIPK297Q,R302L,K304Q
of the respective receptors. The overall structure of the β1AR is presented in (i) while only
). The deﬁning F and LL residues of the respective F(X)6LL ER exportmotifs are indicated in
lls or clonal cell lines stably expressing HA-tagged hIP or its mutated variants, as indicated.
ts. Data presented are representative of three independent experiments. D. Radioligand
the presence of 4 nM [3H]iloprost at 30 °C for 1 hr, where data are presented asmean [3H]
ation in response to stimulation of cell types indicatedwith 1 μMcicaprost, where data are
4). D and E. **pb0.01 and ***pb0.001 indicates that the mean level of [3H]iloprost
as signiﬁcantly reduced in comparison to the wild-type hIP, where applicable. F. HEK.
anti-HA 101R/Alexa Fluor® 594 goat anti-mouse IgG or calnexin with anti-calnexin/Alexa
r overlay) were captured at ×63 magniﬁcation using a Carl Zeiss Laser Scanning System
ependent experiments fromwhich at least 10 ﬁeldswere viewed. Thewhite horizontal bar
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Fig. 6 (continued).
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established that mutation of the critical Lys297 and Lys304 to
corresponding Gln residues generated the hIPK297,304Q that was
retained in the ER, failing to mature into a functional receptor located
at the PM (Fig. 2). Therefore, herein, it was sought to investigate
whether introduction of the F(X)6LL motif into the hIPK297,304Q by
simple substitution of Arg302 to Leu302 would rescue its defect and
allow for export of the resulting hIPK297Q,R302L,K304Q from the ER,
facilitating its maturation and functional expression at the PM.
Noteworthy, molecular modelling using I-TASSER simulations con-
ﬁrmed that the F(X)6LL motif within both the human β1AR (Fig. 6B
(i)) and the hIPK297Q,R302L,K304Q (Fig. 6B (ii)) are located in almost the
same positions, namely predominantly within their corresponding α-
H8 domains in the membrane proximal region of their C-tail domains.
Hence, site-directed mutagenesis was employed to mutate Arg302
to Lys302 in the hIPK297,304Q and the resulting cDNA was stably
transfected into HEK 293 cells to generate the HEK.hIPK297Q,R302L,K304Q
cell line (Fig. 6). Analysis of whole cell protein by western
blotting revealed that, unlike the hIP, the pattern of expression of
the hIPK297Q,R302L,K304Q was similar to the hIPK297,304Q, whereby it was
mainly expressed as the core glycosylated intermediate species (~ 44
and 42 kDa) but the mature, fully glycosylated species (46–66 kDa)
were absent (Fig. 6C, compare hIPK297Q,R302L,K304Q and hIPK297,304Q).
The lack of mature species of the hIPK297Q,R302L,K304Q was further
conﬁrmed by the fact that both [3H]iloprost binding (Fig. 6D, pb0.01)
and cicaprost-induced [Ca2+]i mobilisation (Fig. 6E, pb0.001) were
signiﬁcantly reduced compared to those of the hIP. Furthermore,
image analysis conﬁrmed that the hIPK297Q,R302L,K304Q did not trafﬁc to
the PM, but rather was largely retained in the ER where it co-localised
with calnexin (Fig. 6F). Hence, insertion of the canonical F(X)6LL motif
into the sequence of the ER-retained hIPK297,304Q did not rescue the
defect and result in its export from the ER to the PM. These data maysuggest that the presence of the F(X)6LL motif alone may not be
sufﬁcient to drive ER export of this receptor. Alternatively, the
hIPK297Q,R302L,K304Q receptor may be terminally misfolded resulting in
its accumulation within the ER.
3.6. The effect of substitution of alternative positively charged amino
acids within the novel Lys297, Arg302, Lys304 ER export motif on the
expression and intracellular signalling of the hIP
Data presented herein suggest that the presence of three positively
charged, basic amino acids located at Lys297, Arg302 and Lys304 within
the α-H8 may actually represent a novel ER export motif within the
proximal C-tail of the hIP and may be deﬁned as a K297(X)4R302(X)
K304 or, more generically, as a ‘K(X)4R(X)K’ ER export motif. It was
next sought to further interrogate this ER export motif by investigat-
ing whether there was a strict requirement for these exact amino
acids in the critical Lys297, Arg302 and/or Lys304 positions to facilitate
export of the hIP from the ER or whether Lys or Arg residues could be
substituted for each other in each of those positions. To this end, as
with previous approaches, site-directed mutagenesis in conjunction
with establishment of the respective clonal HEK 293 cell lines, 4
additional variants of the hIPwere generated. These included hIPK297R,
hIPR302K, hIPK304R and hIPK297,304R containing all 4 possible variants
(‘R297(X)4R302(X)K304’, ‘K297(X)4K302(X)K304’, ‘K297(X)4R302(X)R304’
and ‘R297(X)4R302(X)R304’) of the ER export motif (K297(X)4R302(X)
K304) found in the wild type hIP (Fig. 7A).
Western blot analysis of whole cell protein conﬁrmed that the
hIPK297R, hIPR302K, hIPK304R and hIPK297,304R were each expressed as
the mature, fully glycosylated species (46–66 kDa) and as the
immature core glycosylated intermediate species (44 and 42 kDa) in
a pattern similar to that of the wild-type hIP (Fig. 7B). While the
hIPK297R, hIPR302K, hIPK304R and hIPK297,304R displayed minor
Fig. 7. Effect of substituting Lys297, Arg302 and Lys304 with alternative positively charged residues on expression and signalling of the hIP. A. The sequence of the wild-type hIP (residues
297–304) encoding its putative ER export motif (‘K(X)4R(X)K’) is given. Below this, the sequence of the various mutations at Lys297, Arg302 or Lys304 that have been introduced to
interrogate whether similarly charged sequences within the variants hIPK297R (‘R(X)4R(X)K’), hIPR302K (‘K(X)4K(X)K’), hIPK304R (‘K(X)4R(X)R’) or hIPK297,304R (‘R(X)4R(X)R’) might also
serve as a functional ERexportmotif,where the putativemotifs are inbrackets. B.Westernblot analysis (50 μg)ofwhole cell protein fromHEK293 cells or clonal cell lines stably expressing
HA-tagged hIP or its mutated variants, as indicated. The relative positions of themolecular sizemarkers (kDa) are indicated between the blots. Data presented are representative of three
independent experiments. C. Radioligandbinding assayswereperformedoncrudemembrane (P100) fractions fromcell types indicated in thepresenceof4nM[3H]iloprost at 30 °C for 1 hr,
where data are presented as mean [3H]iloprost bound (pmol/mg protein±S.E.M., n=4). D. Agonist-induced intracellular Ca2+ mobilisation in response to stimulation of cell types
indicated with 1 μM cicaprost, where data are presented as mean maximal changes in intracellular Ca2+ mobilised (Δ[Ca2+]i±S.E.M., n=4). E. HEK.hIPK304R cells were ﬁxed and
permeabilised prior to detection ofHA-tagged IPswith anti-HA 101R/Alexa Fluor®594 goat anti-mouse IgG or calnexinwith anti-calnexin/Alexa Fluor® 488 goat anti-rabbit IgG primary/
secondary antibodies, respectively. Images (single or overlay)were captured at ×63magniﬁcation using a Carl Zeiss Laser Scanning System LSM510 and Zeiss LSM Imaging software. Data
presented are representative images from 3 independent experiments from which at least 10 ﬁelds were viewed. The white horizontal bar represents 10 μm.
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[Ca2+]i mobilisation relative to those of the hIP, these reductions were
not signiﬁcant (Fig. 7C and D). Furthermore, as displayed for the
hIPK304R variant, image analysis conﬁrmed that substituting Lys to Arg
residues, and vice versa, or converting them to Lys or Arg residues
exclusively yielded variant hIPs that displayed normal expression at
the PM and did not co-localise with calnexin in the ER (Fig. 7E). Taken
together, these data indicate that it is permissible to substitute one or
more basic residues at positions 297, 302 and 304 in the hIP sequence
for another basic residue without disrupting the ability of these
receptors to be exported from the ER to their functional destination at
the PM and, hence, that any of the variant sequences can serve as an
ER export motif within the hIP.
Consistent with this, bioinformatic analyses and multi-alignment
of the primary IP sequences from various species shows that the
K(X)4R(X)K motif is highly conserved in the proximal C-tail of the
human, mouse, rat, cow and chimpanzee (Fig. 8A). In addition, the
equivalent sequence in the equine IP is the variant K(X)4R(X)R while
that of the canine IP is K(X)4K(X)R, indicating the substitution of
positively charged, basic amino acids in the core motif is indeed
permissible (Fig. 8A). However, multi-alignment of the equivalent
sequences present within members of the broader human prostanoid
receptor subfamily (Fig. 8B), or indeed within the wider GPCR
superfamily as a whole (data not shown), established that the novel‘K(X)4R(X)K’ ER export motif is unique to the IP and is not found in
other related prostanoid or unrelated GPCRs.
Taken together, as depicted in Fig. 8C, consistent with a previous
report [43], I-TASSER structural predictions indicate that the hIP is
organised into the 7 TM α-helices and contains an α-H8 within its
proximal C-tail domain that lies perpendicular to the TM bundle but
parallel to the lipid bilayer to which it associates, at least in part, due
to palmitoylation at the adjacent Cys308, Cys309 and/or Cys311 residues.
Data herein demonstrate that Lys297, Arg302 and Lys304 within the α-
H8 form the critical residues that deﬁne a novel ER export motif
within the hIP but that, consistent with sequences naturally occurring
in IP orthologues from other species, substitution of Lys or Arg
residues within the ‘K(X)4R(X)K’ to generate the variant ‘K/R(X)4 K/R
(X) K/R’ is functionally permissible.
4. Discussion
In the present study, a trafﬁcking signal composed of three
positively charged, basic amino acids, namely Lys297, Arg302 and Lys304
or, simply, K/R(X)4K/R(X)K/R, has been identiﬁed in theα-H8 domain
of the hIP and this is evolutionary conserved in the sequence of the IP
from mouse to man.
The life cycle of all GPCRs consists of a number of distinct phases.
GPCRs are synthesised and subject to a host of co- andpost-translational
Fig. 8. Alignment of Prostacyclin Receptor and human Prostanoid Receptor sequences. A. The sequence of the human IP (Val291 to Leu312) is shown where the critical Lys297, Arg302
and Lys304 residues of its putative ER export motif (‘K(X)4R(X)K’) are in bold. Clustal alignment of the equivalent sequence from the IP from seven orthologues reveal that the ‘K(X)4R
(X)K’ sequence is conserved in the mouse, rat, cow, rabbit and chimpanzee IP sequences and is replaced by the closely related ‘K(X)4R(X)R’ and ‘K(X)4K(X)R’ sequences within the
horse and dog IPs, respectively. B. The sequence of the human IP (Val291 to Leu312) is shown where the critical Lys297, Arg302 and Lys304 residues of its putative ER export motif
(‘K(X)4R(X)K’) are in bold. Clustal alignment of the equivalent sequence from the related human (h) prostanoid receptors including the thromboxane receptor (hTP), prostaglandin
D receptor (DP), prostaglandin E1–E4 receptors (EP1–EP4, respectively) and the prostaglandin F2α receptor (FP) suggests that the “K(X)4R(X)K” motif is not conserved among the
prostanoid receptor family of GPCRs. A and B. The sequences were aligned to show maximum homology using the Clustal W software [94]. Throughout the alignments, identical
amino acids are indicated by asterisks (*); conservative substitutions are indicated by colons (:); and gaps inserted to optimise the alignments are indicated by hyphens (-).
Sequences are based on the published sequences or on those submitted to the GenBankTM/EMBL Data Bank. TM 7, transmembrane domain 7; C-tail, carboxyl-terminal tail domain.
C. I-TASSER three-dimensional structural analysis of the hIP predicts that it contains 7 TM, typical of its GPCR structure, and that K297–V307 (insets; plane and cross-sectional views),
within its proximal C-tail domain, is organised into the eighth α-helical domain (α-H8). Data herein establish that K297, R302 and K304, within α-H8, form the essential residues of a
novel 8 amino acid ER export motif, deﬁned by K/R(X)4K/R(X)K/R, within the hIP, where X represents any amino acid.
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before correctly folded receptors are transported to the Golgi complex.
Once at the Golgi, they are further post-translationally modiﬁed,
including complex glycosylation, beforemature receptors are trafﬁcked
to their functional destination at the PM [45,59]. GPCRs become
activated upon ligand binding to the extracellular and/or TM domains,
leading to rapid phosphorylation, desensitisation and internalisation.
Internalised receptors may then be recycled back to the PM or targeted
to the lysosomes for degradation [60,61]. This intracellular trafﬁcking of
GPCRs is a tightly regulated and dynamic process, which plays a major
part indetermining the level of receptor expression at the PM.While the
events following ligand binding to GPCRs at the PM have been
extensively studied, the processes regulating the anterograde transport
of newly synthesised GPCRs from the ER to the PM remain compara-
tively less well understood. However, recent studies have shed new
insights into the key events involved in the trafﬁcking of GPCRs from the
ER through the Golgi complex to the PM.
Export of newly synthesised GPCRs from the ER is the ﬁrst step in
intracellular trafﬁcking and it is a dynamic, highly regulated event
that has a marked effect on their expression and function at the cell
surface. A quality control system is in place in the ER such that only
correctly folded and assembled receptors are transported to the Golgi
complex [59,62]. The ER contains molecular chaperones to assist
protein folding and to prevent the export of non-native or misfolded
proteins. Shouldmisfolded proteins accumulate in the ER, two distinct
but interconnected mechanisms may be activated. The unfolded
protein response (UPR) acts to increase the folding capacity of the ER
by increasing the levels of chaperones and enzymes [63] while the
ERAD response recognises terminally misfolded proteins and retro-
translocates them from the ER to the cytosol where they are
ubiquitinated and targeted for degradation by the 26S proteasome
[64,65].GPCRs are now known to be part of multiprotein networks and
many accessory proteins interact with them to mediate or modulate
their signalling [66]. These GPCR-interacting proteins (GIPs), such as
receptor activity modifying proteins (RAMPs) and the Homer
proteins, may also directly interact with GPCRs to stabilise their
conformation and therefore enhance maturation [44,67,68]. Further-
more, it has now become accepted that many GPCRs exist as dimers
and/or oligomers [69,70]. Dimerisation of some GPCRs has been
demonstrated to occur in the ER and this may be required for their ER
export, as demonstrated for the metabotropic γ-aminobutyric acid
(GABA) receptor and the β2-AR [71,72]. Trafﬁcking of GPCRs is also
regulated by a large variety of Rab GTPases which act as keymolecular
switches to integrate intracellular signalling and are involved in all
facets of vesicular protein transport [73,74].
In addition to such events and interacting proteins, a number of
structural motifs have been identiﬁed in the primary sequence of
many GPCRs which play a major role in their export from the ER
[44,45]. Once correctly folded, GPCRs enter ER exit sites where they
are exported to the Golgi complex. Protein transport from the ER is
mediated exclusively by coat protein (COP)II vesicles andmany GPCRs
possess these speciﬁc ER export motifs which may bind to
components of the COPII vesicles [44]. To date, most of the ER export
motifs identiﬁed have been located in the proximal C-tail domain of
GPCRs and contain hydrophobic amino acids. The E(X)3LL motif
(where E is Glu, X is any amino acid and L is Leu) is essential for cell
surface targeting of the V2 vasopressin receptor [75]. The F(X)3F(X)3F
motif (where F is Phe and X is any amino acid) is required for cell
surface expression of the dopamine 1 receptor (D1R) [76]. Likewise,
the FN(X)2LL(X)3L motif (where F is Phe, N is Asn, X is any amino acid
and L is Leu) is required for ER export of the human vasopressinV1b/
V3 receptor [77]. Furthermore, as outlined earlier, the F(X)6LL motif
(where F is Phe, X is any amino acid and L is Leu or Ile) is required, at
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the AT1R from the ER [46,47]. In fact, this F(X)6LL motif is highly
conserved in the C-tail domain of many, but not all, GPCRs and is
postulated to provide a common mechanism directing ER to cell
surface trafﬁcking of GPCRs [47]. It should also be noted that while the
majority of the ER export motifs identiﬁed to date are located in the
membrane-proximal C-tail domain, additional studies have identiﬁed
putative motifs in different regions of GPCRs which may be
responsible, at least in part, for ER export. For example, a single Met
residue in the N-terminus and a single conserved Leu residue in IC1
loop also appear to be required for ER export of the α2B-AR [78,79].
While such structural motifs are responsible for the export of
GPCRs from the ER, other ER retention signals/motifs have been also
identiﬁed which actually prevent even correctly folded proteins being
transported from the ER. For example, the RXR motif (where R is Arg
and X is any amino acid), originally identiﬁed in the ATP-sensitive K+
channel, prevents the export of proteins from the ER [80]. Alterna-
tively, other motifs such as the KDEL (where K is Lys, D is Asp, E is Glu
and L is Leu) and the KKXX (where K is Lys and X is any amino acid)
motifs are believed to function as retrieval signals by recycling
proteins from the Golgi complex back to the ER [81]. More recently,
an evolutionary conserved hydrophobic sequence in the extracellu-
lar N-terminus of the α2C-AR was shown to regulate its cellular
processing and PM expression. The wild-type α2C-AR contains the
sequence ALAAALAAAAA (where A is Ala and L is Leu) and is nor-
mally retained in the ER in Rat1 ﬁbroblast and HEK293 cells. Re-
moval of this sequence signiﬁcantly improves PM expression of the
receptor [82].
In the current study, analysis of the C-tail domain of the hIP did not
reveal a sequence matching any of the currently known ER export or
ER retention motifs typically associated with GPCRs. Therefore, it was
sought to identify the sequences required for transport of the hIP from
the ER to the PM. To this end, through mutational analysis, Lys297 and
Lys304 were found to be critical for maturation of the hIP while
Ala-scanning mutagenesis also identiﬁed Arg302 as the only other
residue important for normal trafﬁcking of the hIP. Therefore, these
data suggested that Lys297, Arg302 and Lys304 constituted a putative ER
export motif solely composed of positively charged, basic amino acids,
deﬁned by K(X)4R(X)K, whichwere absolutely required for the export
of the wild-type hIP from the ER to its functional destination at the
PM. Subsequently, it was established that it was indeed permissible
to substitute one or more of these Lys or Arg residues for another
positively charged residue without affecting the ability of the
resulting receptors to be exported from the ER to the PM in a manner
similar to the wild-type hIP. Moreover, alignment of the primary
sequences of the IP from a number of mammalian species veriﬁed that
the variant K/R(X)4K/R(X)K/R motif is evolutionarily conserved and,
hence, substitution of one positively charged residue of the sequence
for another is functionally permissible.
These Lys297, Arg302 and Lys304 basic residues are also of signiﬁcant
interest because they lie within the putative eighth α-helical domain
(α-H8) of the hIP. The ﬁrst evidence for the existence of this α-H8
arose from x-ray crystallography studies of the rhodopsin receptor [4].
This domain lies parallel to the PM and perpendicular to the TM
helices, and it was well positioned to directly interact with the PM,
such as through acylation/palmitoylation of nearby Cys residue(s). In
contrast, theα-H8may adopt a loop-like or disordered structure in an
aqueous environment or in the conformationally active receptor
[7,83,84]. Further experimental and computational studies predicted
that the α-H8 is likely to be a general feature of GPCRs which,
signiﬁcantly, was also shown to be important for many of their
functions, such as expression and intracellular trafﬁcking, G-protein
coupling and activation, dimerisation, internalisation and signalling
[6–8,10].
Rab11a mediates the recycling of certain GPCRs, including the hIP,
from the endosomal recycling compartment to the PM via the so-called “long” recycling pathway [42]. In the case of the hIP, a direct
interaction between its α-H8 domain and Rab11a was recently
established [34]. This represented the ﬁrst demonstration of a direct
interaction between Rab11a and the α-H8 domain of any GPCR and
the Rab11a-binding domain (RBD) of the hIP was localised to a
sequence of 14 residues spanning the region from Val299–Leu312
including a major part of α-H8 (Val299–Val307) adjacent to the
palmitoylated residues at Cys308–Cys311 [34]. In that study, the entire
RBD domain of the hIP was subject to Ala-scanningmutagenesis and it
was established that the hydrophobic residues Phe300, Leu303, Leu305
and Val307, mainly orientated on one face of theα-H8 domain, provide
the interface to which Rab11a actually binds [34]. In addition,
evidence for a role for the positively charged Arg302 and Lys304
residues in inﬂuencing the interaction between the hIP and Rab11a
was also provided, but could not be veriﬁed due to the failure of the
hIPR302A and hIPK304A variants to be expressed at the PM. I-TASSER
simulations [56,57] predict that in the optimal hIP structure, the
positively charged Lys297 and Lys304 lie on the same face of the α-H8
domain opposite to that of Arg302 (Fig. 8C; plane and cross-sectional
views). Importantly, however, the structure and indeed orientation of
those residues in the newly synthesised hIP temporarily resident in
the ER, en route to its ultimate functional destination at the PM, is
unknown. Accordingly, the K(X)4R(X)K motif is likely to be important
in the early stages of the life cycle of the hIP bymediating its transport
from the ER to the Golgi complex, perhaps by facilitating the
interaction of the correctly folded receptor in the ERwith components
of the COPII vesicles. It is possible that some or all of these residues in
α-H8 that are involved in ER to Golgi transport may also be required
to facilitate further interactions of the hIP, for example, with other Rab
(s) such as at different stages of the life cycle of the hIP. Rab proteins
are localised to the cytosolic face of intracellular membranes where
they regulate distinct steps in membrane trafﬁcking [74,85]. Rab1 is
localised to the ER and the Golgi and is involved in anterograde
transport of certain GPCRs from the ER to the Golgi and within the
Golgi itself [86–88]. Rab8 regulates post-Golgi trafﬁcking of certain
GPCRs, such as theα2B-AR and the β2-AR, and this was shown to occur
through a direct interaction of the latter receptors with Rab8 [89]. As
mentioned previously, Arg302 and Lys304 of the hIP appear to be
required, at least in part, for its interaction with Rab11a, which is
involved in recycling of internalised hIP to the PM [34]. Therefore,
disruption of the K(X)4R(X)K ER export motif may also disrupt
association of the hIP with a member(s) of the Rab family of proteins,
which are highly involved in intracellular trafﬁcking of GPCRs. Such
possible interactions with speciﬁc members of the Rab family of 70
proteins or other unidentiﬁed proteins are, of course, entirely
speculative at this point and greater clariﬁcation would require
extensive additional experimentation to identify such protein(s).
The importance of a cluster of positively charged, basic amino acids
in the C-tail domain of GPCRs for their trafﬁcking from the ER through
to the Golgi complex and onwards to the cell surface has previously
been shown for certain other receptors. For example, a membrane-
proximal basic domain, in conjunction with a neighbouring cluster of
Cys residues that are targets for palmitoylation, was absolutely
required for efﬁcient transport and expression of the CCR5 chemokine
receptor at the cell surface [90]. Mutation of Arg319, Lys320 or Arg321
in α-H8 of the melanin-concentrating hormone 1 receptor (MCH1R)
led to a decrease in cell surface expression and, furthermore, a
signiﬁcant decrease in calcium inﬂux was evident with the Arg319and
Lys320 single or double mutants but not with the Arg321 mutant [91].
Additionally, the human follicle stimulating hormone receptor
(hFSHR) possesses two basic BXXBB motifs (where B represents a
basic amino acid residue and X a non-basic residue) in the
juxtamembrane region of its IC3 loop and the C-tail, respectively.
The basic motif in IC3 loop was required for coupling of the activated
receptor to Gαs, whereas the motif in the C-tail was required for PM
expression [92].
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heterologous expression system, these data do provide the ﬁrst
evidence for the presence of a structural motif composed of three
basic amino acids with the sequence K/R(X)4K/R(X)K/R in theα-H8 of
the hIP which is absolutely required for its export from the ER and
expression at the PM. To highlight its importance, it appears that this
basic motif is evolutionarily conserved in the IP from a number of
other mammalian species. However, it is noteworthy that this
transmembrane-proximal α-H8 of the hIP is potentially involved in
a number of complex interactions with intracellular proteins.
Trafﬁcking and processing of the hIP is a complicated process relying
not only on the presence of this ER export motif in α-H8 but also
on the coordination of a host of other events such that functional
receptors may be expressed at the PM. Defective protein transport has
been linked to the pathogenesis of a variety of human diseases,
including cystic ﬁbrosis and Alzheimer's disease [93]. Therefore, it
would be of interest to further deﬁne the molecular mechanism by
which the K/R(X)4K/R(X)K/R motif regulates ER export of the hIP and
to identify the protein(s) selectively interacting with this motif.
Moreover, numerous nonsynonymousmutations have been identiﬁed
within the coding sequence of the hIP that are linked with increased
risk of deep vein thrombosis and the dysfunctional R212C mutation is
associated with intimal hyperplasia [23]. Hence, further knowledge of
the factors regulating the maturation and functional expression of the
hIP is essential and may provide a rationale for the identiﬁcation of
therapeutic or surrogate approaches to rescue its expression where
normal physiologic function is impaired.
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